Related Experiment Video
Updated: Jun 5, 2026
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Management of clopidogrel hypersensitivity without drug interruption.
Kimberly L Campbell1, John R Cohn, David L Fischman
1Division of Cardiology, Jefferson Medical College, Philadelphia, PA, USA.
The American Journal of Cardiology
|January 21, 2011
Summary
Clopidogrel hypersensitivity in patients post-percutaneous coronary intervention can be managed without drug interruption. Short-term corticosteroids and antihistamines effectively resolve symptoms, allowing continued clopidogrel therapy and preventing stent thrombosis.
Area of Science:
- Cardiology
- Pharmacology
- Immunology
Background:
- Clopidogrel hypersensitivity affects up to 6% of patients, often necessitating drug discontinuation.
- Conventional desensitization requires drug withdrawal, posing a risk of stent thrombosis after percutaneous coronary intervention (PCI).
Purpose of the Study:
- To evaluate a strategy for treating clopidogrel hypersensitivity without interrupting the medication.
- To assess the efficacy of corticosteroids and antihistamines in facilitating physiologic tolerance to clopidogrel.
Main Methods:
- A cohort of 25 patients with clopidogrel hypersensitivity post-PCI received suppressive therapy with corticosteroids and/or antihistamines.
- Treatment success was defined as symptom resolution without clopidogrel interruption.
- Outcomes included duration of clopidogrel therapy and adverse cardiac events during long-term follow-up.
Main Results:
- Treatment success was achieved in 22 out of 25 patients (88%), with sustained symptom resolution.
- Clopidogrel therapy was continued long-term in successfully desensitized patients (mean 417 days).
- No deaths, myocardial infarctions, or stent thrombosis occurred during a mean follow-up of 670 days.
Conclusions:
- Clopidogrel hypersensitivity can be effectively managed with short-course corticosteroids and antihistamines without interrupting antiplatelet therapy.
- This approach allows for sustained clopidogrel use, crucial for patients post-PCI, with a low risk of adverse cardiac events.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:26Peptic Ulcer Disease IV: Management
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:29Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...